DE69736351D1 - Methoden und mittel zur hemmung der cdk4-aktivität - Google Patents

Methoden und mittel zur hemmung der cdk4-aktivität

Info

Publication number
DE69736351D1
DE69736351D1 DE69736351A DE69736351A DE69736351D1 DE 69736351 D1 DE69736351 D1 DE 69736351D1 DE 69736351 A DE69736351 A DE 69736351A DE 69736351 A DE69736351 A DE 69736351A DE 69736351 D1 DE69736351 D1 DE 69736351D1
Authority
DE
Germany
Prior art keywords
cdk4
activity
methods
sup
cdk4 activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69736351A
Other languages
German (de)
English (en)
Other versions
DE69736351T2 (de
DE69736351T4 (de
Inventor
Kathryn L Ball
David P Lane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609521.1A external-priority patent/GB9609521D0/en
Priority claimed from GBGB9621314.5A external-priority patent/GB9621314D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DE69736351D1 publication Critical patent/DE69736351D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69736351A 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität Expired - Fee Related DE69736351D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9609521.1A GB9609521D0 (en) 1996-05-08 1996-05-08 Substances and their therapeutic use
GBGB9621314.5A GB9621314D0 (en) 1996-10-09 1996-10-09 Substances and their therapeutic use
PCT/GB1997/001250 WO1997042222A1 (en) 1996-05-08 1997-05-08 Methods and means for inhibition of cdk4 activity

Publications (1)

Publication Number Publication Date
DE69736351D1 true DE69736351D1 (de) 2006-08-31

Family

ID=26309279

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69736351A Expired - Fee Related DE69736351D1 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität
DE69736351T Expired - Lifetime DE69736351T4 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69736351T Expired - Lifetime DE69736351T4 (de) 1996-05-08 1997-05-08 Methoden und mittel zur hemmung der cdk4-aktivität

Country Status (7)

Country Link
US (3) US6962792B1 (enExample)
EP (1) EP0898580B9 (enExample)
JP (1) JP4205165B2 (enExample)
AT (1) ATE333465T1 (enExample)
AU (1) AU2707797A (enExample)
DE (2) DE69736351D1 (enExample)
WO (1) WO1997042222A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity
GB9727277D0 (en) * 1997-12-23 1998-02-25 Medical Res Council Assay
WO1999042821A2 (en) * 1998-02-18 1999-08-26 Theryte Limited Treating cancer
EP1338652A3 (en) * 1998-03-23 2004-05-19 E.I.Du pont de nemours and company Plant cell cyclin genes
BR9907965A (pt) * 1998-03-23 2000-12-12 Du Pont Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, polipetìdios, processo de alteração do nìvel de expressão de uma proteìna ciclina em uma célula hospedeira, método de obtenção de um fragmento de ácido nucleìco, produto e método de avaliação de pelo menos um composto quanto à sua capacidade de inibir a atividade de uma proteìna ciclina
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
EP1165793A2 (en) * 1999-04-07 2002-01-02 E.I. Du Pont De Nemours And Company Cyclin dependent kinase inhibitor genes from plants
US20050153894A1 (en) * 1999-11-30 2005-07-14 Cyclacel Limited p21 peptides
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
GB2369823B (en) * 1999-11-30 2003-06-04 Cyclacel Ltd Assays for cyclin-interacting compounds
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
AU2003258095A1 (en) * 2002-08-07 2004-02-25 Exelixis, Inc. MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0229151D0 (en) 2002-12-13 2003-01-15 St Georges Entpr Ltd Product and method
WO2005040207A1 (en) * 2003-10-20 2005-05-06 F. Hoffmann-La Roche Ag Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
US20090286738A1 (en) * 2005-06-29 2009-11-19 St. George's Enterprises Limited Gene Regulation
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
CN112236162A (zh) 2018-04-06 2021-01-15 昂科莱奇公司 用于裂解选择性癌细胞的组合物
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
CN118324906A (zh) * 2024-06-14 2024-07-12 上海交通大学医学院附属上海儿童医学中心 p21特异性修饰的抗体及制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759164A1 (de) 1977-12-31 1979-07-12 Basf Ag Photopolymerisierbare ueberzugs- und aufzeichnungsmaterialien, enthaltend einen photoinitiator und eine organische halogenverbindung
US5229018A (en) 1986-02-24 1993-07-20 Forrest Gabriel T Completion and workover fluid for oil and gas wells comprising ground peanut hulls
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
CA2146965C (en) 1992-10-16 2003-07-29 David H. Beach Cyclin complex rearrangement and uses related thereto
GB9305448D0 (en) 1993-03-17 1993-05-05 British Tech Group Semiconductor structure and method of manufacturing same
CA2170641C (en) 1993-08-30 2011-11-15 James R. Smith Senescent cell-derived inhibitors of dna synthesis
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
DE69533804T2 (de) 1994-05-24 2006-05-11 Baylor College Of Medicine, Houston Mimetika von aus alternden Zellen abgeleiteten Hemmern der DNA-Synthese
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509557D0 (en) 1995-05-11 1995-07-05 Univ Dundee PCNA binding substance
CA2227370A1 (en) 1995-07-20 1997-02-06 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1997042222A1 (en) 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity

Also Published As

Publication number Publication date
WO1997042222A1 (en) 1997-11-13
AU2707797A (en) 1997-11-26
US20080249025A1 (en) 2008-10-09
DE69736351T2 (de) 2007-07-12
EP0898580A1 (en) 1999-03-03
ATE333465T1 (de) 2006-08-15
US6962792B1 (en) 2005-11-08
DE69736351T4 (de) 2009-07-23
EP0898580B1 (en) 2006-07-19
EP0898580B3 (en) 2008-10-29
JP2000513805A (ja) 2000-10-17
US20040214765A1 (en) 2004-10-28
JP4205165B2 (ja) 2009-01-07
EP0898580B9 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
DE69736351D1 (de) Methoden und mittel zur hemmung der cdk4-aktivität
EP1322307A4 (en) METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
ATE354588T1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
WO2003029418A3 (en) Proliferation and differentiation of stem cells using extracellular matrix and other molecules
ATE552270T1 (de) Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren
EP2261667A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
WO2003072599A3 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
AU7934900A (en) Method of screening for inhibitors of asp2
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL149416A0 (en) Human enzymes of the metalloprotease family
EP1887082A3 (en) TADG-15: An extracellular serine protease overexpressed in carcinomas
AU7216498A (en) Inhibitors of the urokinase receptor
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
WO2004043371A3 (en) Methods and compositions for modulating p53 transcription factor
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
WO2004096991A3 (en) Bcl2l12 polypeptide activators and inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee